To obtain a better understanding on the comparative effectiveness of dabigatran versus Vitamin K antagonist (VKA) for stroke prevention in patients with Non-valvular atrial fibrillation (NVAF) in a real-life setting.
Study Type
OBSERVATIONAL
Enrollment
56,039
As prescribed by treating physicians
As prescribed by treating physicians
Unnamed facility
New York, New York, United States
Incidence of Hospitalization Events (composite endpoint)
Time frame: Within 2 years of starting treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.